Table 1 Individual patient characteristics.

From: EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis

Case

Stage

Mutation type

Mutated

Sex/Age

Smoking

Pathological

Neoadjuvant

Adjuvant

First-line treatment

Response

exons

status

subtype

1

IV

G719S+L861Q

18, 21

70/F

Never

Acinar

None

Cisplatin + Gemcitabine

Gefitinib

PR

2

Ia

709ET=>D

18

51/F

Never

MIA

None

None

None

N/A

3

IIIa

709ET=>D

18

43/M

Ever

Acinar

None

Cisplatin + Docetaxel

Cisplatin + Gemcitabine

PD

4

Ia

G719A

18

71/F

Never

Lepidic

None

None

None

N/A

5

Ib

F723I+L858R

18, 21

58/F

Never

Acinar

None

None

Fluorouracil

N/A

6

IIIa

V689L+L858R

18, 21

43/F

Never

Papillar

None

Cisplatin + Vinorelbine

Radiotherapy

PD

7

Ib

G719A+I768S

18, 20

77/F

Never

Lepidic

None

None

None

N/A

8

Ib

G719S+del746ELREA

18, 19

60/F

Never

Acinar

None

None

None

N/A

9

IIIa

G719A

18

84/M

Never

Acinar

None

None

None

N/A

10

IIIa

E709K+G719S

18

54/F

Never

Acinar

None

Cisplatin + Gemcitabine

None

N/A

11

IIIb

G719A

18

64/M

Ever

Papillar

None

Cisplatin + Vinorelbine

Cisplatin + Gemcitabine

PD

12

Ib

G719A+L861Q

18, 21

74/F

Never

Acinar

None

None

None

N/A

13

IIIa

L692V+L858R

18, 21

63/F

Never

Acinar

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

None

PR

14

IIIa

G719C+S768I

18, 20

77/M

Ever

Papillar

None

Cisplatin + Gemcitabine

None

N/A

15

IIIa

G719S+T790M

18, 20

66/F

Never

Solid

None

None

Carboplatin + Gemcitabine

PR

16

Ia

G719A+S768I

18, 20

62/F

Never

Lepidic

None

None

None

N/A

17

Ia

E709K+L858R

18, 21

53/F

Never

Acinar

None

None

None

N/A

18

IV

E709K+G719C

18

46/F

Never

Acinar

None

Cisplatin + Gemcitabine

Cisplatin + Pemetrexed

PD

19

Ia

709ET=>D

18

38/F

Never

Acinar

None

None

None

N/A

20

Ia

Q701L+L858R

18, 21

64/F

Never

Acinar

None

None

None

N/A

21

Ia

G724S+S768I

18, 20

47/F

Never

Papillar

None

Cisplatin + Pemetrexed

Cisplatin + Docetaxel

SD

22

IIIa

709ET=>D

18

47/F

Never

Solid

None

None

Carboplatin + Gemcitabine

PD

23

Ia

E709K+L858R

18, 21

58/F

Never

Papillar

None

None

Gefitinib

PR

24

IV

E709A+G719E

18

67/F

Never

Acinar

None

None

None

N/A

25

Ia

G719S

18

84/F

Never

Papillar

None

None

Cisplatin + Gemcitabine

SD

26

Ia

G719C+S768I

18, 20

57/M

Never

Acinar

None

None

None

N/A

27

IIa

G719S+S768I

18, 20

64/F

Never

Solid

None

Carboplatin + Gemcitabine

None

N/A

28

Ia

E709A+G719S

18

74/F

Never

Papillar

None

None

None

N/A

29

IIa

G719A

18

57/M

Ever

Acinar

None

None

None

N/A

30

Ia

I706T+L861Q

18, 21

59/F

Never

MIA

None

None

None

N/A

31

Ia

G719C+S768I

18, 20

54/M

Ever

Lepidic

None

None

None

N/A

32

Ia

G719C+S768I

18, 20

57/F

Never

Acinar

None

None

None

N/A

33

IIa

G719A

18

61/F

Never

Solid

Cisplatin + Pemetrexed

None

None

SD

34

Ib

E709K+K757R

18, 19,

68/F

Never

Papillar

None

None

None

N/A

Ā Ā 

+L858R

21

Ā Ā Ā Ā Ā Ā Ā 
  1. F, female; M, male; MIA, minimally invasive adenocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease; N/A, not applicable. Response was evaluated against the neoadjuvant or the first-line treatment.